GlassScriptPhysician profile
Azemina Durgutovic
NPI 1194483305
$2,745.83
in general payments reported to CMS, 2019-2025
45 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,593 · 2023: $943 · 2024: $44.17 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.74 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $407.49 | 2022-2023 | |
| Incyte Corporation | $263.27 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $211.63 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Genzyme Corporation | $129.30 | 2022-2023 | |
| Gilead Sciences, INC. | $124.91 | 2022-2024 | |
| Pfizer INC. | $116.01 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $112.09 | 2022-2023 | Keytruda, Welireg |
| Amgen INC. | $103.57 | 2022-2025 | Otezla, Repatha |
| Seagen INC. | $90.16 | 2022-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $88.47 | 2022-2023 | Enhertu |
| Beigene USA, INC. | $86.45 | 2022-2023 | Brukinsa |
| Celgene Corporation | $85.69 | 2022-2023 | Pomalyst |
| Jazz Pharmaceuticals INC. | $85.44 | 2022-2023 | |
| Astellas Pharma US INC | $82.08 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.03 | 2022-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azemina Durgutovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.